Related Experiment Video

Updated: Aug 30, 2025

Isolation and Culture Expansion of Tumor-specific Endothelial Cells
10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

11.3K

Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy

Parisa Mohammadi1, Reza Yarani2, Azam Rahimpour3

  • 1Medical Biology Research Center, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Drug Metabolism Reviews
|August 29, 2022
PubMed

Insights

Targeting endothelial cell metabolism offers a novel strategy to inhibit pathological angiogenesis in diseases like cancer. Understanding these metabolic pathways is key to developing more effective anti-angiogenic therapies.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Pathology

Background:

  • Pathological angiogenesis underlies diseases such as cancer, maculopathies, and retinopathies.
  • Current anti-angiogenic therapies face limitations due to incomplete knowledge of angiogenesis pathways and inhibitor efficiency.
  • Endothelial cells (ECs) drive angiogenesis through an 'angiogenic switch,' influenced by metabolic changes.

Approach:

  • This review examines endothelial cell metabolic pathways in both normal physiological conditions and the tumor microenvironment (TME).
  • It investigates how the TME alters EC metabolism, presenting unique therapeutic targets.
  • The focus is on identifying and verifying metabolic pathways suitable for novel anti-angiogenic therapies.

Key Points:

  • Endothelial cells undergo a 'metabolic switch' during the 'angiogenic switch,' altering their behavior.
  • EC metabolism differs significantly within the TME compared to normal conditions.
  • Targeting these specific metabolic alterations in ECs presents a promising therapeutic avenue.

Conclusions:

  • Metabolic reprogramming of ECs is central to pathological angiogenesis.
  • Targeting EC metabolic pathways offers a promising strategy for developing new anti-angiogenic drugs.
  • Further research into EC metabolism in the TME is crucial for advancing therapeutic interventions.
Keywords:
Tumor microenvironmentangiogenesis inhibitorsmetabolic switchmetabolismtargeted therapiestumor endothelial cell

More Related Videos

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.1K
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K